Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors-Reference-Cited by-同舟云学术

Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors

Published:2021-10-10 Issue:6 Volume:27 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Hassan Eman¹^ORCID,Jonathan Lancashire²,Jayashree Motwani²

Affiliation:

1. Department of Paediatrics NHS Foundation Trust Paediatric Haematology Haematology and Oncology Unit Birmingham Children's Hospital Birmingham UK

2. Department of Paediatric Haematology NHS Foundation Trust Birmingham Children's Hospital Birmingham UK

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14432

Reference28 articles.

1. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A

2. Highlights of prescribing information;HEMLIBRA®;HEMLIBRA,2017

3. European Medicines Agency (EMA).Hemlibra. Amsterdam Netherlands: EMA;2018. Available from:https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra

4. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

5. Emicizumab prophylaxis in hemophilia A with inhibitors;Oldenburg J;N Engl J Med,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

2. Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry;Haemophilia;2024-04-05

3. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence;Haemophilia;2024-01-30

4. Emicizumab: the hemophilia A game changer;Haematologica;2023-11-02

5. Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan;TH Open;2023-07